Bcr-Abl tyrosine kinase inhibitors-current status

Infectious Agents and Cancer

Volumn 8, Issue 1, 2013, Pages

  Mughal, Anum ^a   Aslam, Hafiz Muhammad ^a   Khan, Aga Muhammad Hammad ^b   Saleem, Shafaq ^a   Umah, Ribak ^c   Saleem, Maria ^d  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^c Dinajpur Medical College   (India)

^d UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 THIADIAZOLE DERIVATIVE; ABELSON KINASE; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; CARBOXYLIC ACID; DASATINIB; IMATINIB; ISOLEUCINE; METHYL GROUP; MULTIDRUG RESISTANCE PROTEIN; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

APOPTOSIS; ARTICLE; BINDING SITE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DNA SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; HUMAN; HYDROGEN BOND; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84879094568     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-8-23     Document Type: Article

References (28)

1. A minute chromosome in human chronic granulocytic leukemia. Nowell P, Hungerford D, Landmarks in Medical Genetics: Classic Papers with Commentaries 2004 132 51 103
2. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON, Science (New York, NY) 1988 239 4841 Pt 1 775
3. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Konopka JB, Watanabe SM, Witte ON, Cell 1984 37 3 1035 10.1016/0092-8674(84)90438-0 6204766
4. A new consistent chromosomal adnormality in chronic myelogeneus leukaemia identified by quinacrine fluorescence and Giemsa staining. Rowley JD, Landmarks in Medical Genetics: Classic Papers with Commentaries 2004 243 51 104
5. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Bedi A, Zehnbauer BA, Barber JP, Sharkis S, Jones R, Blood 1994 83 8 2038 2044 8161775 (Pubitemid 24112713)
6. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG, Oncogene 1998 16 3 335 10.1038/sj.onc.1201490 9467959
7. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Cortez D, Stoica G, Pierce JH, Pendergast AM, Oncogene 1996 13 12 2589 9000132
8. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. Bazzoni G, Carlesso N, Griffin JD, Hemler ME, J Clin Investig 1996 98 2 521 10.1172/JCI118820 8755665
9. Presence of the adhesion inhibitory β1B integrin isoform on CML but not normal progenitors is at least in part responsible for the decreased CML progenitor adhesion. Zhao R, Tarone G, Verfaillie C, Blood 1997 90 Suppl 1 393a
10. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Lugo TG, Pendergast A-M, Muller AJ, Witte ON, Science (New York, NY) 1990 247 4946 1079 10.1126/science.2408149
11. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Cortez D, Kadlec L, Pendergast AM, Mol Cell Biol 1995 15 10 5531 5541 7565705
12. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Bixby D, Talpaz M, ASH Education Program Book 2009 2009 1 461 476
13. Imatinib: a selective tyrosine kinase inhibitor. Manley P, Cowan-Jacob S, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J, Eur J Cancer 2002 38 19 S27 12647701
14. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Asaki T, Sugiyama Y, Hamamoto T, Higashioka M, Umehara M, Naito H, Niwa T, Bioorg Med Chem Lett 2006 16 5 1421 1425 10.1016/j.bmcl.2005. 11.042 16332440 (Pubitemid 43143035)
15. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Eck MJ, Manley PW, Curr Opin Cell Biol 2009 21 2 288 10.1016/j.ceb.2009.01.014 19217274
16. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. An X, Tiwari AK, Sun Y, Ding P-R, Ashby CR, Chen Z-S, Leuk Res 2010 34 10 1255 1268 10.1016/j.leukres. 2010.04.016 20537386
17. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Stein B, Douglas Smith B, Clin Ther 2010 32 5 804 820 10.1016/j.clinthera.2010.05.003 20685492
18. Active transport of imatinib into and out of cells: implications for drug resistance. Thomas J, Wang L, Clark RE, Pirmohamed M, Blood 2004 104 12 3739 3745 10.1182/blood-2003-12-4276 15315971 (Pubitemid 39564452)
19. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Jabbour E, Cortes J, Kantarjian H, Core evidence 2009 4 207
20. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Manley PW, Cowan-Jacob SW, Mestan J, Biochim Biophys Acta 2005 1754 1-2 3 13 16172030 (Pubitemid 41797682)
21. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N, Bioorg Med Chem 2010 18 19 6977 6986 10.1016/j.bmc.2010.08.026 20817538
22. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Breccia M, Alimena G, Leuk Res 2010 34 2 129 134 10.1016/j.leukres.2009.08.031 19783301
23. Dasatinib: a new step in molecular target therapy. Olivieri A, Manzione L, Ann Oncol 2007 18 suppl 6 22i42 vi46 17591830
24. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA III, Bohacek RS, Blood 2004 104 8 2532 2539 10.1182/blood-2004-05-1851 15256422 (Pubitemid 39331857)
25. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Blood 2005 106 12 3948 3954 10.1182/blood-2005-06-2209 16105974 (Pubitemid 41739036)
26. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Horio T, Hamasaki T, Inoue T, Wakayama T, Itou S, Naito H, Asaki T, Hayase H, Niwa T, Bioorg Med Chem Lett 2007 17 10 2712 2717 10.1016/j.bmcl.2007.03.002 17376680 (Pubitemid 46636265)
27. Discovery and SAR of 1, 3, 4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Radi M, Crespan E, Botta G, Falchi F, Maga G, Manetti F, Corradi V, Mancini M, Santucci MA, Schenone S, Bioorg Med Chem Lett 2008 18 3 1207 1211 10.1016/j.bmcl.2007.11.112 18078752 (Pubitemid 351179316)
28. Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? Valent P, Eur J Clin Investig 2010 40 10 918 931 10.1111/j.1365-2362.2010.02328.x